Melinta Therapeutics (Fusidic Acid) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Melinta Therapeutics (Fusidic Acid) General Information

Description

Fusidic acid is orally active against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus strains (MRSA).

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 300 George Street
  • Suite 301
  • New Haven, CT 06511
  • United States
Primary Industry
Buildings and Property
Other Industries
Other Business Products and Services
Acquirer
Arrevus
Corporate Office
  • 300 George Street
  • Suite 301
  • New Haven, CT 06511
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Melinta Therapeutics (Fusidic Acid) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Melinta Therapeutics (Fusidic Acid)‘s full profile, request access.

Request a free trial

Melinta Therapeutics (Fusidic Acid) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Melinta Therapeutics (Fusidic Acid)‘s full profile, request access.

Request a free trial

Melinta Therapeutics (Fusidic Acid) FAQs

  • Where is Melinta Therapeutics (Fusidic Acid) headquartered?

    Melinta Therapeutics (Fusidic Acid) is headquartered in New Haven, CT.

  • What industry is Melinta Therapeutics (Fusidic Acid) in?

    Melinta Therapeutics (Fusidic Acid)’s primary industry is Buildings and Property.

  • Is Melinta Therapeutics (Fusidic Acid) a private or public company?

    Melinta Therapeutics (Fusidic Acid) is a Private company.

  • What is Melinta Therapeutics (Fusidic Acid)’s current revenue?

    The current revenue for Melinta Therapeutics (Fusidic Acid) is .

  • Who are Melinta Therapeutics (Fusidic Acid)’s investors?

    Melinta Therapeutics has invested in Melinta Therapeutics (Fusidic Acid).

  • When was Melinta Therapeutics (Fusidic Acid) acquired?

    Melinta Therapeutics (Fusidic Acid) was acquired on 05-Feb-2019.

  • Who acquired Melinta Therapeutics (Fusidic Acid)?

    Melinta Therapeutics (Fusidic Acid) was acquired by Arrevus.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process